Open Access
Review

Table 1

Characteristics of included studies.

Reference Peptide name given by authors Reference standard Index test Peptide concentration Clinical research phase Clinical form evaluated Case origin Causative Leishmania species
Bremer Hinckel, B.C. et al., 2019 [7] EpQ11 Parasitology, serology (rK39 or rK28) ICT (cassette) ND I VL Sudan ND
ICT (dipstick) ND
Carmelo, E. et al., 2002 [10] 23061 Parasitology ELISA 20 μg/mL I CL Peru ND
23063
23065
23067
23069
23071
23073
Carvalho, A.M.R.S. et al., 2018 [11] Peptide-1 Molecular technique ELISA 10 μg/well II VL Brazil L. infantum
Peptide-2 10 μg/well
Peptide-3 10 μg/well
Peptide-4 10 μg/well
Peptide-5 10 μg/well
Peptide-6 10 μg/well
Mix I 3.34 μg for each one peptide/well
Mix II 1.66 μg for each one/well
Mix III 5.0 μg for each one/wel
Mix IV 5.0 μg for each one/well
Costa, L.E. et al., 2016 [15] A10 Parasitology, molecular technique Phage-ELISA 1.00E + 08 phages/well II TL Brazil L. braziliensis
B7
B10
C11
C12
H7
Costa, L.E. et al., 2017 [16] B10 Peptide Molecular technique, serology (Kalazar detect Test) ELISA 2 μg/well I VL Brazil L. infantum
C01 Peptide
Costa, M.M. et al., 2012 [17] 47 Parasitology (VL patients); molecular technique (control group) ELISA 40 μg/mL, 4 μg/well I VL Brazil ND
17
18
19
13
Mix peptides 13 + 19
Mix peptides 18 + 19
Mix peptides 13 + 47
Mix peptides 17 + 47
Mix peptides 19 + 47
Galvani N.C. et al., 2021 [26] Pept1 Molecular technique (VL patients); serological test (Kalazar detect Rapid test kit, Inbios) (control group) ELISA 5 μg/well II VL Brazil L. infantum
Pept2
Pept3
Pept4
Pept5
Pept6
Pept7
Pept8
Galvani N.C. et al., 2022 [27] Pept1 Parasitology, molecular technique ELISA 5 μg/well II TL Brazil L. braziliensis
Pept2
Pept3
Pept4
Pept5
Pept6
Pept7
Pept8
Gonzales et al., 2002 [29] 23083 Parasitology ELISA 20 μg/mL I TL Peru ND
23089
23085
Link, J.S. et al., 2017 [35] P1 Parasitology ELISA 0.25 μg/well I CL Brazil L. braziliensis
P2
P3
Mix P1+P2+P3
Machado, A.S. et al., 2020 [37] PeptC Molecular technique (VL patients); serology (control group) ELISA 10 μg/well II VL Brazil L. infantum
Medeiros et al. 2022 [40] peptide Parasitology, molecular technique ELISA 1 μg/well II TL Brazil L. braziliensis
Menezes-Souza, D. et al., 2014 [42] Peptide 1 Parasitology, molecular technique ELISA 10 μg/well II TL Brazil L. braziliensis (TL); L. infantum (VL)
VL
Peptide 2 TL
VL
Peptide 3 TL
VL
Menezes-Souza, D. et al., 2015a [43] Peptide-1 Parasitology, molecular technique ELISA 10 μg/well II TL Brazil ND
VL
Peptide-2 TL
VL
Menezes-Souza, D. et al., 2015b [41] Peptide-1 Parasitology, molecular technique ELISA 10 μg/well II TL Brazil ND
VL
Oliveira-da-silva, J.A. et al., 2020a [47] Peptide Molecular technique ELISA 2 μg/well II VL Brazil L. infantum
Oliveira-da-silva, J.A. et al., 2020b [48] PeptJ Molecular technique (VL patients); serology (control group) ELISA 2 μg/well II VL Brazil L. infantum
Ramos F.F. et al., 2021 [58] Pep1 Molecular technique (VL and VL/HIV-coinfeted patients), serological test (Kalazar detect Rapid test kit) (control group) ELISA 2.5 μg/well II VL Brazil L. infantum
Pep2 5 μg/well
Pep3 5 μg/well
Pep4 2.5 μg/well
Pep5 1.25 μg/well
Pep6 1.25 μg/well
Pep7 1.25 μg/well
Pep8 2.5 μg/well
Pep9 1.25 μg/well
Salles, B.C.S. et al., 2017 [62] A3 Molecular technique (VL patients); parasitology, molecular technique (TL patients) Phage-ELISA 1.00E+08 phages/well II VL Brazil L. infantum
A5
A8
A11
B2
B9
H11
G12
Salles, B.C.S. et al., 2019 [63] Peptide Parasitology and molecular technique (TL patitents); serology (control group) ELISA 1.5 μg/well II TL Brazil L. braziliensis
Vale, D.L. et al., 2019 [69] Peptide Molecular technique ELISA 1 μg/well II VL Brazil L. infantum
Vale, D.L. et al., 2022 [70] PepA Molecular technique ELISA 5 μg/well II TL and VL Brazil L. braziliensis (TL); L. infantum (VL)
PepB
PepC
PepD
PepE
PepF
PepG

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.